Knobbe Martens
Joined Patexia at Aug 10, 2016
Knobbe Martens
3 days ago
Written by: Zachary B. Grinovich Mitral regurgitation is the most common form of valvular heart disease and affects around 10% of Americans over 75. It occurs when the mitral valve, which is located between the left atrium and the left ventricle, doesn’t close properly. This causes blood to leak backward from the... Read More
Knobbe Martens
Written by:Makoto Tsunozaki, Ph.D. and Jane Dai, Ph.D. We previously reported a decision by the U.S. Food and Drug Administration (FDA), denying the premarketing authorization of several flavored e-cigarette product.[1]  On April 2, 2025, the Supreme Court of the United States unanimously vacated and remanded the decision by the U.S.... Read More
Knobbe Martens
4 days ago
PTAB Litigation
Written by: Matthew Pham and Jacob R. Rosenbaum CERAMTEC GMBH v. COORSTEK BIOCERAMICS LLC Before Lourie, Taranto, and Stark.  Appeal from the United States Patent and Trademark Office, Trademark Trial and Appeal Board. Summary: A utility patent may still be considered strong evidence of a claimed trade dress’s functionality even if... Read More
Knobbe Martens
4 days ago
PTAB Litigation
Written by: Luke D. Holbrook and Jacob R. Rosenbaum DOLLAR FINANCIAL GROUP, INC. v. BRITTEX FINANCIAL, INC. [OPINION] Before Prost, Taranto, and Hughes.  Appeal from the United States Patent and Trademark Office, Trademark Trial and Appeal Board. Summary: The zone of natural expansion doctrine cannot not be used to establish priority... Read More
Knobbe Martens
Apr 1, 2025
Written by: Phillip J. Minnick, Ph.D.   Zydus Lifesciences Limited announced on March 11, 2025, that it entered into an agreement to acquire a majority stake in Amplitude Surgical. Reports state that Zydus Lifesciences has a tender offer agreement with PAI Partners, Amplitude Surgical’s management and two minority shareholders. Under the agreement, Zydus Lifesciences would acquire 85.6%... Read More
Knobbe Martens
Mar 25, 2025
Written by: Douglas W. Crandell, Ph.D. and Eric Furman, Ph.D. Drug development programs face unique challenges in demonstrating the safety and effectiveness of drugs for treating rare diseases.  The FDA’s Accelerating Rare disease Cures (ARC) Program started the Learning and Education to Advance and Empower Rare Disease Drug Developers (LEADER 3D)... Read More